Archives: Agenda

• What are key blockers and decision-making factors preventing or accelerating the use of AI
• Where is it currently being used within the clinical trial lifecycle and how has it been implemented
• What tools and systems are being used and how to select the right service provider
• Overcoming barriers, sharing challenges and successes
• Where do we see the evolvement of AI within clinical trials in 5-10 years time?

Moderator: TBC

• Ensuring patient understanding of rights and informed consent
• Reaching underserved communities and reducing enrolment stigma
• Running trials more efficiently and effectively with patient burden in mindFatiha Adams

• Selecting recruitment partners and collaborating with advocacy groups, patient organizations and care givers to extend patient reach
• Communicating effectively and working together with sites to assist in recruitment
• Complying with regulation across differing therapeutic areas
• Finding innovative solutions to reduce patient burden

Moderator: TBC

Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Hosted by industry experts and each focused on a single issue, roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

Each roundtable session lasts for 30 minutes and delegates may attend up to 2 roundtables

Roundtable 1: Creating effective clinical vendor strategies and partnerships
Amanda Hovda, Director, Clinical Vendor Strategy and Partnerships, Agios Pharmaceuticals

Roundtable 2: Sharing thoughts on diversity in clinical trials: how much focus remains on this?
Deborah Waltz, Vice President Quality Assurance, Cullinan Therapeutics

Roundtable 3: Running clinical trials inside or outside the USA: benefits and challenges
Ros Cheetham, Vice President Clinical Operations, MacroGenics

Roundtable 4: Creating a robust clinical trial design
Nicole Leedom, VP Head of Clinical Operations, SpringWorks Therapeutics

Roundtable 5: Discussing how individuals are utilizing AI in clinical trials
Katherine Neblett, Global Program Director, AstraZeneca

• Defining evolving relationships between sponsors and CROs
• Highlighting challenges and hurdles and how to overcome them
• Creating trust and transparency to enhance partnerships
• Outlining governance and oversight structures, working towards shared goals and KPIs

• Defining a global operational model aligned with program and regulatory objectives
• Managing vendor oversight and fostering collaborative relationships
• Ensuring delivery resilience amid complexity, variability and disruption
• Embedding quality and compliance to ensure inspection readiness